HealthEquity (HQY) Reports Q3 Earnings: What Key Metrics Have to Say
https://www.zacks.com/stock/news/2193838/healthequity-hqy-reports-q3-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-2193838
Dec 05, 2023 - While the top- and bottom-line numbers for HealthEquity (HQY) give a sense of how the business performed in the quarter ended October 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
0
Reasons to Add DexCom (DXCM) Stock to Your Portfolio Now
https://www.zacks.com/stock/news/2199515/reasons-to-add-dexcom-dxcm-stock-to-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2199515
Dec 18, 2023 - DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
0
Here's Why You Should Retain QuidelOrtho (QDEL) Stock for Now
https://www.zacks.com/stock/news/2199972/here-s-why-you-should-retain-quidelortho-qdel-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2199972
Dec 19, 2023 - QuidelOrtho's (QDEL) strong product portfolio raises optimism about the stock.
0
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
https://www.zacks.com/stock/news/2202089/reasons-to-retain-pacbio-pacb-stock-in-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2202089
Dec 26, 2023 - PacBio's (PACB) product development activities raise optimism about the stock.
0
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
https://www.zacks.com/stock/news/2205238/reasons-to-retain-quest-diagnostics-dgx-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2205238
Jan 03, 2024 - Investors are optimistic about Quest Diagnostics (DGX) on strength in base business and strategic collaborations.
0
Here's Why Investors Should Retain Abbott (ABT) Stock Now
https://www.zacks.com/stock/news/2207160/here-s-why-investors-should-retain-abbott-abt-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2207160
Jan 08, 2024 - Investors are optimistic about Abbott (ABT) led by solid prospects in the Diagnostic business and raised guidance.
0
QIAGEN (QGEN) Gains From New Alliances Amid FX Headwind
https://www.zacks.com/stock/news/2207546/qiagen-qgen-gains-from-new-alliances-amid-fx-headwind?cid=CS-ZC-FT-analyst_blog|zer_report_update-2207546
Jan 09, 2024 - QIAGEN (QGEN) is progressing well with its testing menu expansion strategy, which is driving the company's growth.
0
Quest Diagnostics (DGX) to Boost Lab Services With New Buyout
https://www.zacks.com/stock/news/2207650/quest-diagnostics-dgx-to-boost-lab-services-with-new-buyout?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2207650
Jan 09, 2024 - Quest Diagnostics' (DGX) recent acquisition seeks to increase accessibility to cutting-edge, high-caliber and reasonably priced laboratory services.
0
Here's Why Investors Should Retain Integra (IART) Stock Now
https://www.zacks.com/stock/news/2208088/here-s-why-investors-should-retain-integra-iart-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2208088
Jan 10, 2024 - Investors remain optimistic about Integra (IART) due to the positive outlook for its CSS segment.
0
LabCorp (LH) to Expand Clinical Trails Access With New Pact
https://www.zacks.com/stock/news/2208988/labcorp-lh-to-expand-clinical-trails-access-with-new-pact?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2208988
Jan 11, 2024 - LabCorp (LH) and Hawthorne Effect hope to enhance decentralized clinical trials by merging existing services and developing fresh, unique service offers.
0